Short Interest in Cocrystal Pharma, Inc. (NASDAQ:COCP) Rises By 186.5%

Cocrystal Pharma, Inc. (NASDAQ:COCP) was the target of a significant increase in short interest in June. As of June 15th, there was short interest totaling 410,154 shares, an increase of 186.5% from the May 31st total of 143,168 shares. Currently, 4.9% of the company’s stock are short sold. Based on an average daily volume of 108,694 shares, the short-interest ratio is presently 3.8 days.

Institutional Trading of Cocrystal Pharma

A hedge fund recently bought a new position in Cocrystal Pharma stock. T3 Companies LLC purchased a new position in Cocrystal Pharma, Inc. (NASDAQ:COCP) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 52,300 shares of the company’s stock, valued at approximately $51,000. T3 Companies LLC owned 0.38% of Cocrystal Pharma as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 6.72% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings raised shares of Cocrystal Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, June 8th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has an average rating of “Sell”.

Cocrystal Pharma Trading Up 0.5%

Shares of COCP traded up $0.01 during mid-day trading on Friday, reaching $1.01. The company’s stock had a trading volume of 67,851 shares, compared to its average volume of 102,689. The stock has a market cap of $14.00 million, a P/E ratio of -1.39 and a beta of 1.42. Cocrystal Pharma has a 1-year low of $0.86 and a 1-year high of $2.67. The business has a 50-day simple moving average of $1.19 and a two-hundred day simple moving average of $1.11.

Cocrystal Pharma (NASDAQ:COCP) last released its quarterly earnings data on Friday, May 15th. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02). The business had revenue of $0.23 million for the quarter, compared to analysts’ expectations of $0.23 million. Research analysts anticipate that Cocrystal Pharma will post -0.69 EPS for the current year.

Cocrystal Pharma Company Profile

Cocrystal Pharma, Inc (NASDAQ:COCP) is a clinical-stage biotechnology company focused on the discovery and development of novel antiviral therapeutics. Utilizing an integrated structure-guided drug design platform, the company combines x-ray crystallography, computational chemistry and medicinal chemistry to identify and optimize small molecule inhibitors targeting key viral enzymes. This approach is intended to accelerate the progression of lead candidates from discovery through preclinical development.

The company’s pipeline includes multiple preclinical programs aimed at treating respiratory and systemic viral infections.